Skip to main navigation menu Skip to main content Skip to site footer

Admin menu

Volume 13 (2026): Issue 1

Use of eptacog beta for perioperative haemostatic management in major surgery in people with haemophilia A and inhibitors receiving emicizumab prophylaxis: A US case series

Abstract

Introduction: Bypassing agents are required for bleed management in people with haemophilia A and inhibitors (PwHAI) undergoing major surgery, including patients on prophylaxis. In the setting of prophylaxis with emicizumab, recombinant activated factor VII (rFVIIa) is the preferred bleed treatment class for these patients. Eptacog beta is the newest addition in the rFVIIa product class in the US and is approved in the surgical setting in the EU. The aim of this report is to describe the safety, effectiveness, and real-world use of eptacog beta for perioperative bleed control during major surgery in PwHAI in the US using emicizumab prophylaxis.

Methods: This is a retrospective case series describing eight PwHAI on emicizumab prophylaxis who used eptacog beta for perioperative bleed control during major surgery (six arthroplasties, one radical nephrectomy, and one transforaminal lumbar interbody fusion) from five centres in the US. Patient characteristics, medical history, perioperative eptacog beta usage, intraoperative surgical and haemostatic outcomes, and postoperative outcomes are described.

Results: All participants achieved haemostatic control with eptacog beta during major surgery using doses ranging from 70 to 225 µg/kg (median: 76.9 µg/kg). A median of 17 doses (range: 9–77) was used per participant. Participants were treated for a median of 5.75 days (range: 2–29). One case included intraoperative tranexamic acid and thrombin. Four individuals were switched to other haemostatic agents postoperatively due to lack of sufficient eptacog beta stock in the hospital pharmacy. Three participants received eptacog beta for the entirety of the postoperative period. One participant received eptacog alfa pre- and intraoperatively and switched to eptacog beta in the postoperative period. Intraoperatively, there were no adverse bleeding events and no need for transfusions. Postoperatively, there were no bleeds, thromboembolic events, or hospital readmission within 30 days due to bleeding or thrombosis.

Conclusions: Eptacog beta provided adequate haemostatic control during and after major surgical procedures in PwHAI who were on prophylaxis with emicizumab, with no safety signals observed.

 

Plain Language Summary

People with haemophilia A who develop inhibitors have a higher risk of bleeding, particularly during major surgery. Even when these individuals receive prophylaxis with emicizumab, additional treatments such as bypassing agents are often needed to help control bleeding during and after surgery. Eptacog beta is a newer bypassing agent that has been approved for use in people with haemophilia A and inhibitors. This study reviewed the medical records of eight people with haemophilia A and inhibitors who were receiving emicizumab prophylaxis and underwent major surgery at five treatment centres in the United States. The surgeries included six joint replacement procedures, one kidney removal, and one spinal fusion procedure. All patients received eptacog beta, a recombinant activated factor VII (rFVIIa) bypassing agent, to help control bleeding during and/or after surgery. All eight patients achieved successful bleeding control. No excessive bleeding events occurred during the operations, and no patients required blood transfusions. Following surgery, no bleeding episodes, blood clots, or hospital readmissions related to bleeding or thrombosis within 30 days of surgery were reported. In some cases, patients were switched to alternative treatments after surgery due to limited hospital supply of eptacog beta, and not due to treatment failure. These findings suggest that eptacog beta can provide effective and safe bleeding control during and after major surgery in people with haemophilia A and inhibitors who are receiving emicizumab prophylaxis. Although the study included a small number of patients, the results add to the growing evidence supporting the use of eptacog beta in the surgical setting.

Article

View Full Article

References

  • 1. Escobar M, Luck J, Averianov Y, et al. PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant human FVIIa) in perioperative care in subjects with haemophilia A or B with inhibitors. Haemophilia 2021; 27(6): 911-920. doi: 10.1111/hae.14418.
  • 2. Jiménez-Yuste V. Non-factor therapies for hemophilia: achievements and perspectives. Semin Thromb Hemost 2025;51(1):23-27. doi: 10.1055/s-0044-1796651.
  • 3. Prudente TP, Camelo RM, Guimarães RA, Roberti M. Emicizumab prophylaxis in people with hemophilia A and inhibitors: a systematic review and meta-analysis. Sao Paulo Med J 2024; 142(5): e2023102. doi: 10.1590/1516-3180.2023.0102.R1.20022024.
  • 4. Van Thillo Q, Hermans C. Rebalancing agents in hemophilia: knowns, unknowns, and uncertainties. Haematologica 2025; 110(12): 2902-2912. doi: 10.3324/haematol.2025.288245.
  • 5. Linari S, Castaman G. Concomitant use of rFVIIa and emicizumab in people with hemophilia A with inhibitors: current perspectives and emerging clinical evidence. Ther Clin Risk Manag 2020; 16: 461-469. doi: 10.2147/tcrm.S205310.
  • 6. Seaman CD, Ragni MV. Emicizumab use in major orthopedic surgery. Blood Adv 2019; 3(11): 1722-1724. doi: 10.1182/bloodadvances.2019000228.
  • 7. Oldenburg J, Mahlangu JN, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377(9): 809-818. doi: 10.1056/NEJMoa1703068.
  • 8. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 Suppl 6: 1-158. doi: 10.1111/hae.14046.
  • 9. National Bleeding Disorders Foundation (NBDF). MASAC Document #268 – Recommendation on the use and management of emicizumab-kxwh (Hemlibra) for hemophilia A with and without inhibitors. 2022. Available from https://www.bleeding.org/sites/default/files/document/files/268_Emicizumab.pdf (accessed March 11, 2026).
  • 10. Santagostino E, Mancuso ME, Novembrino C, et al. Management of joint replacement in hemophilia A with inhibitors during emicizumab prophylaxis. Blood 2017; 130 (Supplement 1):2360. doi: 10.1182/blood.V130.Suppl_1.2360.
  • 11. Castaman G, Linari S, Pieri L, et al. Safe and successful surgical outcome in persons with hemophilia A with and without inhibitors treated with emicizumab: A large, single center, real-world experience. J Clin Med 2023; 12(6): 2317. doi: 10.3390/jcm12062317.
  • 12. Ju HY, Jang HL, Park YS. The efficacy of bypassing agents in surgery of hemophilia patients with inhibitors. Blood Res 2015; 50(3): 173-178. doi: 10.5045/br.2015.50.3.173.
  • 13. Carulli C, Daniele G, Linari S, et al. Major orthopaedic surgery in persons with haemophilia A with and without inhibitors treated by emicizumab: A mid-term, large, and successful series at a single center. J Clin Med 2024; 13(9): 2646. doi: 10.3390/jcm13092646.
  • 14. Castaman G, Peyvandi F, Kremer Hovinga JA, et al. Surgical experience from the STASEY study of emicizumab prophylaxis in people with hemophilia A with factor VIII inhibitors. TH Open 2024; 8(1): e42-e54. doi: 10.1055/s-0043-1777766.
  • 15. Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost 2018; 16(12): 2362-2374. doi: 10.1111/jth.14296.
  • 16. US Food and Drug Administration (FDA). Sevenfact: Summary basis for regulatory action. 2020. Available from https://www.fda.gov/media/137275/download (accessed March 12, 2026).
  • 17. Sevenfact (eptacog beta) Prescribing Information. Louisville, KY: HEMA Biologics; June 23, 2024.
  • 18. Cevenfacta (eptacog beta) Summary of Product Characteristics. Puteaux, France: Laboratoire Français du Fractionnement et des Biotechnologies; November 29, 2022. Available from https://www.ema.europa.eu/en/documents/product-information/cevenfacta-epar-product-information_en.pdf.
  • 19. European Medicines Agency (EMA). Cevenfacta (eptacog beta [activated]). 2022. Available from https://www.ema.europa.eu/en/documents/overview/cevenfacta-epar-medicine-overview_en.pdf.
  • 20. Youkhana K, Batsuli G, Acharya S, et al. Real-world effectiveness of eptacog beta in patients with haemophilia and inhibitors: A multi-institutional case series. Haemophilia 2024; 30(6): 1321-1331. doi: 10.1111/hae.15094.
  • 21. Chrisentery-Singleton T, Acharya S, Ahuja S, et al. Safety and real-world effectiveness of eptacog beta with emicizumab prophylaxis: an interim analysis of ATHN 16. Blood Vessel Thromb Hemost 2026: 3(3): 100169. doi: 10.1016/j.bvth.2026.100169.
  • 22. A phase 3 study of the safety and efficacy of coagulation Factor VIIa (Recombinant) for the prevention of excessive bleeding in patients with congenital hemophilia A or B with inhibitors to Factor VIII or IX undergoing elective major surgical procedures SCOPE HIM (SCOPE HIM) (NCT05695391). 2022. Available from https://clinicaltrials.gov/study/NCT05695391 (accessed March 16, 2026).
  • 23. Santagostino E, Lentz SR, Misgav M, et al. Safety and efficacy of turoctocog alfa (NovoEight®) during surgery in patients with haemophilia A: results from the multinational guardian™ clinical trials. Haemophilia 2015; 21(1): 34-40. doi: 10.1111/hae.12518.
  • 24. Martin de Bustamante JM, Rivas-Pollmar MI, Acedo N, Butta N, Jimenez-Yuste V, Álvarez-Román MT. Real-world experience with eptacog beta for on-label and off-label indications: The Spanish experience. Pharmaceuticals (Basel) 2025; 18(11): 1640. doi: 10.3390/ph18111640.
  • 25. George AR, Sylvester KW, Kanaan DM, et al. Real world experience with use of coagulation factor VIIa at an academic medical center. Clin Appl Thromb Hemost 2025; 31: 10760296251405425. doi: 10.1177/10760296251405425.
  • 26. Ciolek AM, Arnall J, Moore DC, Palkimas S, Der-Nigoghossian J, Dane K. Eptacog beta for bleeding treatment and prevention in congenital hemophilia A and B with inhibitors: A review of clinical data and implications for clinical practice. Ann Pharmacother 2022; 56(7): 831-838. doi: 10.1177/10600280211049394.
  • 27. Alexander WA, Jensen I, Hathway J, et al. Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements. J Manag Care Spec Pharm 2022; 28(5): 518-527. doi: 10.18553/jmcp.2022.21197.

PDF Download

Download PDF

Open in full-page viewer

Authors

  • Miguel A Escobar

    ORCID iD
    miguel.escobar@uth.tmc.edu
    Gulf States Hemophilia and Thrombophilia Center, Houston, Texas, USA
    The University of Texas Health Science Center at Houston (ROR ID)
  • Sonia Nasr

    ORCID iD
    GLOVAL LLC, Broomfield, Colorado, USA
  • David Doherty

    ORCID iD
    The University of Texas Health Science Center at Houston (ROR ID)
  • John C Quinn

    ORCID iD
    Mischer Neuroscience Associates, Houston, Texas
  • Tyler W Buckner

    ORCID iD
    University of Colorado Health (ROR ID)
  • Madeleine Ochs

    ORCID iD
    Michigan Medicine (ROR ID)
  • Lauren Shevell

    ORCID iD
    University of Michigan (ROR ID)
  • Kylee L Martens

    ORCID iD
    Oregon Health & Science University (ROR ID)
  • Doris Quon

    ORCID iD
    Orthopaedic Institute for Children (ROR ID)
  • Steven W Pipe

    ORCID iD
    University of Michigan (ROR ID)